Search for author "Ron Simon"

• You have accessRestricted access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini and Thomas A. Kent

  Stroke. 2013;44:1525-1531, originally published May 24, 2013

  https://doi.org/10.1161/STROKEAHA.113.001116

  Download PDF
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  

  Figure.

  Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by...

  Show More

  Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.

  Show Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 1.

  Post-Euclidean Matching ResultsShow More

  Post-Euclidean Matching ResultsShow Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 2.

  Post-Euclidean Matching for Black Women Treated With Placebo or Recombinant Tissue-Type Plasminogen ActivatorShow More

  Post-Euclidean Matching for Black Women Treated With Placebo or Recombinant Tissue-Type Plasminogen ActivatorShow Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 3.

  Postmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Bi...Show More

  Postmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 4.

  Postmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birm...Show More

  Postmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
• You have accessRestricted access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini and Thomas A. Kent

  Stroke. 2013;44:1525-1531, originally published May 24, 2013

  https://doi.org/10.1161/STROKEAHA.113.001116

  Download PDF
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  

  Figure.

  Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by...

  Show More

  Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.

  Show Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 1.

  Post-Euclidean Matching ResultsShow More

  Post-Euclidean Matching ResultsShow Less
• You have access

  Explicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and Sex

  Pitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. Kent

  Stroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116

  View table

  Table 2.

  Post-Euclidean Matching for Black Women Treated With Placebo or Recombinant Tissue-Type Plasminogen ActivatorShow More

  Post-Euclidean Matching for Black Women Treated With Placebo or Recombinant Tissue-Type Plasminogen ActivatorShow Less

Pages